New York (Vocus) 29 September 2010

Mount Sinai School of Medicine has signed a contract worth almost 0.5 million received the National Institutes of Health (NIH) and National Heart and Lung Institute (NHLBI) through the Programme Centre of Excellence for Nanotechnology (PEN ). The contract is awarded one of four at the national level to develop multi-disciplinary research centers to develop nanotechnology tools for diagnosis and treatment of heart, lung and blood diseases. As Co-Principal Investigator, Zahi A. Fayad, PhD, professor of radiology and medicine and director of the Translational and Molecular Imaging Institute at Mount Sinai School of Medicine led a team of internationally recognized experts in cardiac care, imaging and bioengineering. He is joined by the Centera? S other Co-Principal Investigator, Robert S. Langer, ScD, Massachusetts Institute of Technology designed for this very co-operative program with the help of nanotechnology to better prevent and treat cardiovascular diseases.

a leading authority in cardiovascular medicine and vision plans, Mount Sinai a center, organizing and developing the state of the art translation nanoparticles to help treat and prevent atherosclerosis, heart attack and heart failure. During the contract period of five years, the investigators at Mount Sinai and other institutions involved in adopting a threefold approach to the problem of heart disease. Investigators are exploring minimally invasive advances based on nanotechnology, to regenerate damaged tissue after a heart attack. They develop nano therapies defective resulting inflammation of atherosclerosis focused on repair? Theranostics â? or to allow the use of nanotechnology diagnostic treatment of atherosclerosis.

â? There is huge potential in the use of nanotechnology to cardiovascular disease to treat, but remained largely unexplored, â? Said Dr. Fayad. â? Through this research, we hope to show that nano-therapies may unprecedented performance in preventing the progression of heart disease and improve the safety and effectiveness of existing treatments.â p> ???? In addition to pioneering research objectives of the PEN Center on Mount Sinai is to create the center a unique training program focuses on the development of nanomedicine translation tools for diagnostic imaging and minimally invasive treatment of diseases, cardiovascular. PhD Mount Sinai? S continue to translational research, the program will emphasize the importance of translating the discoveries after the signing ceremony for the establishment of patient care.

â? We are honored to be chosen as one of the main survey sites on the program was a pen? Said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Mount Sinai School of Medicine and executive vice president for academic affairs at Mount Sinai Medical Center. â? The objectives of this program represent Mount Sinai? s to make an unwavering commitment to translational research, and the doors of our world-renowned physician-scientists reveal significant progress in the prevention and treatment of cardiovascular disease? ?

more Fayad, leader of the Mount Sinai project Valentin Fuster, MD, PhD, director of Mount Sinai Heart, the Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Roger Hajjar, MD, Director of Research Laboratories of family research and Wiener Cardiovascular-Arthur and Janet Ross, a professor of cardiology, medicine and genetics and cellular medicine and Martin Schwartz, PhD, assistant professor of cardiology and medicine. Other researchers at the Mount Sinai program Willem Mulder, PhD, David Cormode, PhD, Kevin Costa, Ph.D., and Hina Chaudhry, MD. The other institutions involved in this grant, the New York University, Columbia University, Brigham and rubber boots are rain boots? S Hospital and the Massachusetts Institute of Technology.

â? Effects of cardiovascular disease for millions of people and cost billions of dollars each year in the United States alone, â? Dr. Fuster said. â? Mount Sinai Heart has important discoveries over the years to reduce this impact, but can be done much more. This program will allow us the door to new therapeutic and diagnostic approaches using nanotechnology to reduce the burden of cardiovascular disease end open?

â? We are delighted with this wonderful and important opportunities and potential it offers to improve the diagnosis and treatment of cardiovascular diseases and congratulate the NHLBI on this program of translational research, a support? Said Dr. Fayad.

about Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses both Mount Sinai Hospital and Mount Sinai School of Medicine. Founded in 1968, Mount Sinai School of Medicine one of the few medical schools is integrated into a hospital in the United States. He has more than 3,400 teachers in 32 departments and 15 institutes and is ranked among the top 20 medical schools in both the National Institutes of Health, and funding of U.S. News & World Report. The school received in 2009 Spencer Foreman Award for Outstanding Community Service from the Association of American Medical Colleges.

Mount Sinai Hospital, founded in 1852, is a 1171-bed tertiary and quaternary care and education of the nation? s oldest, largest and most-respected voluntary hospitals. In 2009 U.S. News & World Report ranked the Mount Sinai Hospital, among the nations? S 20 best hospitals for the reputation of patient safety and other factors related to patient care. Nearly 60,000 people had occurred on Mount Sinai in hospital last year and 530,000 outpatient visits.

For more information, visit www.mountsinai.org. Follow us on Twitter @ mountsinainyc.


>

clear = “all”
55 active adult community